Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein.

Lenzo FL, Cance WG.

Transl Cancer Res. 2017 Aug;6(Suppl 6):S957-S960. doi: 10.21037/tcr.2017.06.05. No abstract available.

2.

Surgeon-Authored Virtual Laparoscopic Adrenalectomy Module Is Judged Effective and Preferred Over Traditional Teaching Tools.

Kurenov S, Cendan J, Dindar S, Attwood K, Hassett J, Nawotniak R, Cherr G, Cance WG, Peters J.

Surg Innov. 2017 Feb;24(1):72-81. doi: 10.1177/1553350616672971. Epub 2016 Oct 7.

3.

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.

Marlowe TA, Lenzo FL, Figel SA, Grapes AT, Cance WG.

Mol Cancer Ther. 2016 Dec;15(12):3028-3039. Epub 2016 Sep 16.

4.

Synthesis and bioactivity of a Goralatide analog with antileukemic activity.

Li Z, Lebedyeva IO, Golubovskaya VM, Cance WG, Alamry KA, Faidallah HM, Dennis Hall C, Katritzky AR.

Bioorg Med Chem. 2015 Aug 1;23(15):5056-60. doi: 10.1016/j.bmc.2015.04.061. Epub 2015 May 14.

PMID:
26048023
5.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3. Epub 2015 Feb 6.

PMID:
25656374
6.

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG.

Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760.

7.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

8.
9.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

10.

The use of modified four-dimensional computed tomography in patients with primary hyperparathyroidism: an argument for the abandonment of routine sestamibi single-positron emission computed tomography (SPECT).

Kukar M, Platz TA, Schaffner TJ, Elmarzouky R, Groman A, Kumar S, Abdelhalim A, Cance WG.

Ann Surg Oncol. 2015 Jan;22(1):139-45. doi: 10.1245/s10434-014-3940-y. Epub 2014 Jul 30.

PMID:
25074663
11.

Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.

Gogate PN, Kurenova EV, Ethirajan M, Liao J, Yemma M, Sen A, Pandey RK, Cance WG.

Cancer Lett. 2014 Oct 28;353(2):281-9. doi: 10.1016/j.canlet.2014.07.032. Epub 2014 Jul 24.

12.

In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).

Golubovskaya V, Curtin L, Groman A, Sexton S, Cance WG.

Arch Toxicol. 2015 Jul;89(7):1095-101. doi: 10.1007/s00204-014-1290-y. Epub 2014 Jun 12.

PMID:
24915938
13.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.

Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.

Eur J Med Chem. 2014 Jun 10;80:154-166. doi: 10.1016/j.ejmech.2014.04.041. Epub 2014 Apr 15.

14.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

15.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

16.

Translational cancer research for surgeons.

Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):xv-xvi. doi: 10.1016/j.soc.2013.06.013. Epub 2013 Jul 3. No abstract available.

PMID:
24012406
17.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

18.

Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Stewart JE, Ma X, Megison M, Nabers H, Cance WG, Kurenova EV, Beierle EA.

Mol Carcinog. 2015 Jan;54(1):9-23. doi: 10.1002/mc.22070. Epub 2013 Jul 19.

19.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

20.

The role of faecal diversion in low rectal cancer: a review of 1791 patients having rectal resection with anastomosis for cancer, with and without a proximal stoma.

Nurkin S, Kakarla VR, Ruiz DE, Cance WG, Tiszenkel HI.

Colorectal Dis. 2013 Jun;15(6):e309-16. doi: 10.1111/codi.12248.

PMID:
23586660
21.

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Cance WG, Kurenova E, Marlowe T, Golubovskaya V.

Sci Signal. 2013 Mar 26;6(268):pe10. doi: 10.1126/scisignal.2004021. Review.

22.

MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.

Golubovskaya VM, Sumbler B, Ho B, Yemma M, Cance WG.

Anticancer Agents Med Chem. 2014 Jan;14(1):18-28.

23.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

24.

Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Beierle EA, Ma X, Stewart JE, Megison M, Cance WG, Kurenova EV.

Mol Carcinog. 2014 Mar;53(3):230-42. doi: 10.1002/mc.21969. Epub 2012 Oct 12.

25.

FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Heffler M, Golubovskaya VM, Conroy J, Liu S, Wang D, Cance WG, Dunn KB.

Anticancer Agents Med Chem. 2013 May;13(4):584-94.

26.

Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.

Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN.

Cell Cycle. 2012 Sep 1;11(17):3250-9. doi: 10.4161/cc.21611. Epub 2012 Aug 16.

27.

Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM.

J Biol Chem. 2012 May 25;287(22):18656-73. doi: 10.1074/jbc.M111.322883. Epub 2012 Apr 5.

28.

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG.

Carcinogenesis. 2012 May;33(5):1004-13. doi: 10.1093/carcin/bgs120. Epub 2012 Mar 7.

29.

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):546-54.

30.

A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.

Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, Cance WG.

Anticancer Agents Med Chem. 2013 May;13(4):532-45.

31.

Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor.

Shaw CM, Grobmyer SR, Ucar DA, Cance WG, Reith JD, Hochwald SN.

Anticancer Res. 2012 Feb;32(2):439-43.

PMID:
22287730
32.

2011 society of surgical oncology heritage award: honoring Kirby I. Bland, MD.

Cance WG.

Ann Surg Oncol. 2012 Jan;19(1):7-10. doi: 10.1245/s10434-011-2007-6. Epub 2011 Aug 31. No abstract available.

PMID:
21881924
33.

FAK and p53 protein interactions.

Golubovskaya VM, Cance WG.

Anticancer Agents Med Chem. 2011 Sep;11(7):617-9. Review.

34.

Society of surgical oncology presidential address: the war on cancer--shifting from disappointment to new hope.

Cance WG.

Ann Surg Oncol. 2010 Aug;17(8):1971-8. doi: 10.1245/s10434-010-0987-2. Epub 2010 Feb 24. No abstract available.

PMID:
20180028
35.

Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM.

Cell Cycle. 2010 Mar 1;9(5):1005-15. Epub 2010 Mar 14.

36.

Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.

Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, Golubovskaya VM.

Mol Carcinog. 2010 Mar;49(3):224-34. doi: 10.1002/mc.20592.

37.

A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.

Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN.

Mol Carcinog. 2010 Feb;49(2):200-9. doi: 10.1002/mc.20590.

38.

A pilot prospective randomized trial of postoperative epoetin alfa in patients undergoing major operation for upper gastrointestinal malignancy.

Grobmyer SR, Hemming AW, Harris N, Behrns K, Logan H, Kim RD, Chang M, Cance WG, Hochwald SN.

Am J Clin Oncol. 2009 Dec;32(6):570-3. doi: 10.1097/COC.0b013e31819790a8.

PMID:
19675446
39.
40.

Targeting of the protein interaction site between FAK and IGF-1R.

Zheng D, Kurenova E, Ucar D, Golubovskaya V, Magis A, Ostrov D, Cance WG, Hochwald SN.

Biochem Biophys Res Commun. 2009 Oct 16;388(2):301-5. doi: 10.1016/j.bbrc.2009.07.156. Epub 2009 Aug 5.

41.
42.

A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.

Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM.

Cell Cycle. 2009 Aug;8(15):2435-43. Epub 2009 Aug 1.

43.

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.

Kurenova EV, Hunt DL, He D, Fu AD, Massoll NA, Golubovskaya VM, Garces CA, Cance WG.

Cell Cycle. 2009 Jul 15;8(14):2266-80. Epub 2009 Jul 23.

44.

FAK overexpression and p53 mutations are highly correlated in human breast cancer.

Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG.

Int J Cancer. 2009 Oct 1;125(7):1735-8. doi: 10.1002/ijc.24486.

45.

Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.

Kweh F, Zheng M, Kurenova E, Wallace M, Golubovskaya V, Cance WG.

Mol Carcinog. 2009 Nov;48(11):1005-17. doi: 10.1002/mc.20552.

46.

Specific tyrosine phosphorylation of focal adhesion kinase mediated by Fer tyrosine kinase in suspended hepatocytes.

Oh MA, Choi S, Lee MJ, Choi MC, Lee SA, Ko W, Cance WG, Oh ES, Buday L, Kim SH, Lee JW.

Biochim Biophys Acta. 2009 May;1793(5):781-91. doi: 10.1016/j.bbamcr.2009.01.015. Epub 2009 Feb 5.

47.

Is there an indication for initial conservative management of pancreatic cystic lesions?

Grobmyer SR, Cance WG, Copeland EM, Vogel SB, Hochwald SN.

J Surg Oncol. 2009 Oct 1;100(5):372-4. doi: 10.1002/jso.21260.

PMID:
19267387
48.

Focal adhesion kinase and cancer.

Golubovskaya VM, Kweh FA, Cance WG.

Histol Histopathol. 2009 Apr;24(4):503-10. doi: 10.14670/HH-24.503. Review.

PMID:
19224453
49.

Is endoscopic resection of gastric gastrointestinal stromal tumors safe?

Waterman AL, Grobmyer SR, Cance WG, Hochwald SN.

Am Surg. 2008 Dec;74(12):1186-9.

PMID:
19097534
50.

A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG.

J Med Chem. 2008 Dec 11;51(23):7405-16. doi: 10.1021/jm800483v.

Supplemental Content

Loading ...
Support Center